ACKR1 and parasitic infectious disease: At day 60 post-CHMI, 5/12 volunteers of the PvRAS group (42%) were fully protected from the CHMI, while 2/2 mock-immunized Fy + control individuals developed parasitemia determined by microscopy and confirmed by qPCR.